Cargando…
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma
BACKGROUND: Whole-body (WB) MRI, which includes diffusion-weighted imaging (DWI) and T(1)-w Dixon, permits sensitive detection of marrow disease in addition to qualitative and quantitative measurements of disease and response to treatment of bone marrow. We report on the first study to embed standar...
Autores principales: | Rata, Mihaela, Blackledge, Matthew, Scurr, Erica, Winfield, Jessica, Koh, Dow-Mu, Dragan, Alina, Candito, Antonio, King, Alexander, Rennie, Winston, Gaba, Suchi, Suresh, Priya, Malcolm, Paul, Davis, Amy, Nilak, Anjumara, Shah, Aarti, Gandhi, Sanjay, Albrizio, Mauro, Drury, Arnold, Roberts, Sadie, Jenner, Matthew, Brown, Sarah, Kaiser, Martin, Messiou, Christina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334517/ https://www.ncbi.nlm.nih.gov/pubmed/35900614 http://dx.doi.org/10.1186/s13244-022-01253-0 |
Ejemplares similares
-
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study
por: Keaveney, Sam, et al.
Publicado: (2023) -
Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases
por: Donners, Ricardo, et al.
Publicado: (2023) -
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
por: Brown, Sarah, et al.
Publicado: (2021) -
Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial
por: Jenner, Matthew W, et al.
Publicado: (2021) -
Improving real‐world myeloma patient access to whole body MRI through “open‐access” knowledge sharing: The UK experience
por: Kaiser, Martin F, et al.
Publicado: (2020)